Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

OKYO stock hub

OKYO Pharma Limited has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

OKYOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

85.5M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

OKYO

In the news

Latest news · OKYO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROICn/a

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All OKYO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

168

Groups with data

Currency

USD

Showing 168 of 168 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001849296
Company name	OKYO Pharma Limited
Country	United Kingdom
Country code	US
Cusip	679345108
Employees	4
Employees Change	1%
Employees Change Percent	33.33
Enterprise value	$81.5M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2022-05-17
Isin	GG00BMFG5F62
Last refreshed	2026-05-10
Market cap	$85.5M
Market cap category	Micro-Cap
Price	$1.63
Price currency	USD
Sector	Healthcare
Sic	2836
Symbol	OKYO
Website	https://okyopharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-5.39%
FCF yield	-3.62%

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-6.3M
Net Income	$-4.6M
Net Income Growth Years	1%
Profit Per Employee	$-1.2M
ROA	-104.6
Roa5y	-151.6
ROCE	183.1

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	10.95%
Cagr3y	7.3%
EPS Growth Years	2
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$4.6M
Cash	$4.2M
Current Assets	$4.6M
Current Liabilities	$8.1M
Debt	$185,795
Equity	$-3.4M
Interest Coverage	-31.84
Liabilities	$8.1M
Long Term Assets	$1,178
Long Term Liabilities	$0
Net Cash	$4M
Net Cash By Market Cap	$4.72
Tangible Book Value	$-3.4M
Tangible Book Value Per Share	$-0.09
WACC	4.16

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.58
Net Working Capital	$-7.5M
Quick ratio	0.53
Working Capital	$-3.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-24.46%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	10.95%
200-day SMA	2.09
3Y total return	23.53%
50-day SMA	1.62
50-day SMA vs 200-day SMA	50under200
All Time High	5.84
All Time High Change	-72.07%
All Time High Date	2022-05-17
All Time Low	0.81
All Time Low Change	101.86%
All Time Low Date	2024-08-05
ATR	0.11
Beta	-0.05
Beta1y	0.09
Beta2y	0.41
Ch YTD	-21.26
High	1.65
High52	3.35
High52 Date	2025-08-08
High52ch	-51.33%
Low	1.61
Low52	1.32
Low52 Date	2025-05-12
Low52ch	23.49%
Ma50ch	0.49%
Price vs 200-day SMA	-22.05%
RSI	50.97
RSI Monthly	45.35
RSI Weekly	42.79
Sharpe ratio	0.52x
Sortino ratio	0.87
Total Return	-24.46%
Tr YTD	-21.26
Tr1m	1.88%
Tr1w	-1.81%
Tr3m	-15.1%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-0.17
Operating Income	$-6.3M
Price target	$6.33
Price Target Change	$288

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	32,014,681%
Float Percent	61%
Net Borrowing	948,192
Shares Insiders	31.26%
Shares Institutions	1.27%
Shares Out	52,479,257
Shares Qo Q	-17.58%
Shares Yo Y	24.46%
Short Float	0.85%
Short Ratio	2.63
Short Shares	0.52

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-4.5M
Average Volume	75,648.45x
Bv Per Share	-0.09
CAPEX	$-1,208
Ch1m	1.88
Ch1w	-1.81
Ch1y	10.96
Ch3m	-15.1
Ch3y	23.49
Ch6m	-33.47
Change	0.62%
Change From Open	0
Close	1.62
Days Gap	0.62
Depreciation Amortization	2,256
Dollar Volume	72,582.3
Earnings Date	2025-07-18
Earnings Time	bmo
EBIT	$-6.3M
EBITDA	$-6.3M
EPS	$-0.11
F Score	2
FCF	$-3.1M
FCF EV Yield	-3.8x
FCF Per Share	$-0.06
Financing CF	6,421,208
Fiscal Year End	March
Founded	2,007
Income Tax	$-1.8M
Investing CF	-1,208
Ipr	-59.25
Iprfo	-72.07
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2025-07-18
Last Report Date	2025-09-30
Last Split Date	2023-05-22
Last Split Type	Reverse
Last10k Filing Date	2025-07-18
Ma150	1.98
Ma150ch	-17.51%
Ma20	1.6
Ma20ch	1.62%
Net CF	3,233,179
Next Earnings Date	2026-07-17
Open	1.63
Optionable	No
Position In Range	50
Post Close	1.63
Postmarket Change Percent	-1.23
Postmarket Price	$1.61
Ppne	1,178
Price Date	2026-05-08
Relative Volume	0.59x
Share Based Comp	1,356,922
Tr6m	-33.47%
Volume	44,529

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does OKYO pay a dividend?

Capital-return profile for this ticker.

Performance

OKYO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns OKYO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+1.3%

Float: +61.0% of shares outstanding

Insider ownership

+31.3%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

OKYO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

51.0

Neutral momentum band

Price vs 200-day MA

-22.0%

50/200-day relationship not available

Beta (5Y)

-0.05

Less volatile than the market

Sharpe ratio

0.52

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About OKYO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current OKYO stock rating?

OKYO Pharma Limited is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full OKYO analysis?

The full report lives at /stocks/OKYO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for OKYO?

The latest report frames OKYO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the OKYO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.